You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
力生製藥(002393.SZ):藥品替格瑞洛分散片通過上市許可申請

格隆匯6月6日丨力生製藥(002393.SZ)公佈,近日,天津力生製藥股份有限公司收到國家藥品監督管理局頒發的關於替格瑞洛分散片(以下簡稱“該藥品”)90mg規格的《藥品註冊證書》(批件編號:2025S01585),該藥品通過藥品上市許可申請。

替格瑞洛分散片適應症:本品與阿司匹林合用,用於急性冠脈綜合徵(ACS)患者或有心肌梗死病史且伴有至少一種動脈粥樣硬化血栓形成事件高危因素(見臨牀試驗PEGASUS研究)的患者,降低心血管死亡、心肌梗死和卒中的發生率。至少在ACS發病後最初12個月內,本品的療效優於氯吡格雷。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account